Synairgen (SNG) Earns Corporate Rating from FinnCap
Separately, N+1 Singer reiterated an under review rating on shares of Synairgen in a research report on Wednesday, September 6th.
Shares of Synairgen (LON:SNG) opened at GBX 12.88 ($0.17) on Thursday. Synairgen has a 12-month low of GBX 6.88 ($0.09) and a 12-month high of GBX 32 ($0.43).
Synairgen Company Profile
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in preclinical development for the treatment of idiopathic pulmonary fibrosis (IPF).
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.